文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

立体定向体部放射治疗肝细胞癌后通过磁共振成像进行肿瘤反应评估

Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma.

作者信息

Oldrini Guillaume, Huertas Andres, Renard-Oldrini Sophie, Taste-George Hélène, Vogin Guillaume, Laurent Valérie, Salleron Julia, Henrot Philippe

机构信息

Service d'Imagerie, Institut de cancérologie de Lorraine, Vandoeuvre-lès-Nancy Cedex, France.

Service de radiothérapie, Institut de cancérologie de Lorraine, Vandoeuvre-lès-Nancy Cedex, France.

出版信息

PLoS One. 2017 Apr 25;12(4):e0176118. doi: 10.1371/journal.pone.0176118. eCollection 2017.


DOI:10.1371/journal.pone.0176118
PMID:28441447
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5404860/
Abstract

BACKGROUND: To evaluate the MRI features of a tumor response, local control, and predictive factors of local control after stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC). METHODS: Thirty-five consecutive patients with 48 HCCs who were treated by SBRT were included in this retrospective study. All patients provided written informed consent to be treated by SBRT, and prior to inclusion they authorized use of the treatment data for further studies. The assessment was made using MRI, with determination of local and hepatic responses according to Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST) criteria during a two-year follow-up. RESULTS: The local response rate according to mRECIST was higher than with RECIST. A tumor diameter less than 20 mm at baseline was an independent predictive factor for RECIST and mRECIST responses, as was diffusion-weighted signal for RECIST. During follow-up, a tumor diameter of <20 mm (p = 0.034) and absence of a high intensity on T2-weighted (p = 0.006) and diffusion-weighted images (p = 0.039) were associated with a better response according to RECIST. Post-treatment changes include peritumoral ring-like enhanced changes with high intensity on T2-weighted images. CONCLUSIONS: SBRT is a promising technique for the treatment of inoperable HCC. Post-treatment changes on MRI images can resemble tumor progression and as such must be adequately distinguished. The regression of tumorous enhancement is variable over time, although diffusion-weighted and T2-weighted intensities are predictive factors for tumor RECIST responses on subsequent MRIs. They hence provide a way to reliably predict treatment responses.

摘要

背景:评估立体定向体部放射治疗(SBRT)治疗肝细胞癌(HCC)后肿瘤反应、局部控制情况及局部控制的预测因素的MRI特征。 方法:本回顾性研究纳入了35例连续接受SBRT治疗的48例HCC患者。所有患者均提供书面知情同意书接受SBRT治疗,在纳入研究前,他们授权使用治疗数据进行进一步研究。使用MRI进行评估,在两年随访期间根据实体瘤疗效评价标准(RECIST)和改良RECIST(mRECIST)标准确定局部和肝脏反应。 结果:根据mRECIST的局部反应率高于RECIST。基线时肿瘤直径小于20 mm是RECIST和mRECIST反应的独立预测因素,RECIST的扩散加权信号也是如此。随访期间,根据RECIST,肿瘤直径<20 mm(p = 0.034)以及T2加权(p = 0.006)和扩散加权图像上无高强度信号(p = 0.039)与更好的反应相关。治疗后改变包括T2加权图像上肿瘤周围环状强化改变且呈高强度信号。 结论:SBRT是治疗无法手术切除的HCC的一种有前景的技术。MRI图像上的治疗后改变可能类似于肿瘤进展,因此必须进行充分鉴别。肿瘤强化的消退随时间变化,尽管扩散加权和T2加权信号强度是后续MRI上肿瘤RECIST反应的预测因素。因此,它们提供了一种可靠预测治疗反应的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/929a/5404860/3374a76cd105/pone.0176118.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/929a/5404860/9cc084e443b4/pone.0176118.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/929a/5404860/777287b80922/pone.0176118.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/929a/5404860/35bae0122f7d/pone.0176118.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/929a/5404860/f3e7245b9363/pone.0176118.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/929a/5404860/86cb13aa9e43/pone.0176118.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/929a/5404860/9dcc0a7ba8dd/pone.0176118.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/929a/5404860/3374a76cd105/pone.0176118.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/929a/5404860/9cc084e443b4/pone.0176118.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/929a/5404860/777287b80922/pone.0176118.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/929a/5404860/35bae0122f7d/pone.0176118.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/929a/5404860/f3e7245b9363/pone.0176118.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/929a/5404860/86cb13aa9e43/pone.0176118.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/929a/5404860/9dcc0a7ba8dd/pone.0176118.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/929a/5404860/3374a76cd105/pone.0176118.g007.jpg

相似文献

[1]
Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma.

PLoS One. 2017-4-25

[2]
Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria.

AJR Am J Roentgenol. 2019-10-15

[3]
CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.

Eur J Radiol. 2016-1

[4]
Magnetic Resonance Imaging Evaluation of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy: Long Term Imaging Follow-Up.

Int J Radiat Oncol Biol Phys. 2018-9-10

[5]
Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.

J Hepatol. 2017-8-18

[6]
The role of diffusion-weighted magnetic resonance imaging in the treatment response evaluation of hepatocellular carcinoma patients treated with radiation therapy.

Int J Radiat Oncol Biol Phys. 2014-7-15

[7]
Hepatic reaction dose for parenchymal changes on Gd-EOB-DTPA-enhanced magnetic resonance images after stereotactic body radiation therapy for hepatocellular carcinoma.

J Med Imaging Radiat Oncol. 2016-2

[8]
Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.

Radiology. 2013-12-12

[9]
Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy.

Int J Radiat Oncol Biol Phys. 2017-8-24

[10]
Targeting Accuracy of Image-Guided Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Real-Life Clinical Practice: In Vivo Assessment Using Hepatic Parenchymal Changes on Gd-EOB-DTPA-Enhanced Magnetic Resonance Images.

Int J Radiat Oncol Biol Phys. 2018-5-14

引用本文的文献

[1]
Is Apparent Diffusion Coefficient Established as an Imaging Biomarker for Stereotactic Body Radiation Therapy Assessment in Hepatocellular Carcinoma?

Cancer J.

[2]
Response evaluation of hepatocellular carcinoma treated with stereotactic body radiation therapy: magnetic resonance imaging findings.

Abdom Radiol (NY). 2023-6

[3]
Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy.

Clin Transl Radiat Oncol. 2022-8-8

[4]
Liver magnetic resonance imaging for evaluation of response to treatment after stereotactic body radiation therapy of hepatocellular carcinoma.

World J Hepatol. 2022-9-27

[5]
MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review.

Abdom Radiol (NY). 2022-7

[6]
LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy With Radiologic-Pathologic Explant Correlation in Patients With SBRT-Treated Hepatocellular Carcinoma.

Int J Radiat Oncol Biol Phys. 2022-3-1

[7]
SBRT for HCC: Overview of technique and treatment response assessment.

Abdom Radiol (NY). 2021-8

[8]
Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring.

BMC Cancer. 2021-5-3

[9]
Use of Contrast-Enhanced Ultrasound with Sonazoid for Evaluating the Radiotherapy Efficacy for Hepatocellular Carcinoma.

Diagnostics (Basel). 2021-3-9

[10]
A preliminary study of hepatocellular carcinoma post proton beam therapy using MRI as an early prediction of treatment effectiveness.

PLoS One. 2021

本文引用的文献

[1]
Implantation of fiducial markers in the liver for stereotactic body radiation therapy: Feasibility and results.

Diagn Interv Imaging. 2015-6

[2]
Stereotactic body radiotherapy-induced arterial hypervascularity of non-tumorous hepatic parenchyma in patients with hepatocellular carcinoma: potential pitfalls in tumor response evaluation on multiphase computed tomography.

PLoS One. 2014-2-28

[3]
Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma patients who failed or were unsuitable for transarterial chemoembolization.

Eur J Gastroenterol Hepatol. 2014-3

[4]
Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis.

AJR Am J Roentgenol. 2013-12

[5]
Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma.

PLoS One. 2013-11-8

[6]
Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity.

PLoS One. 2013-10-11

[7]
Imaging effects of radiation therapy in the abdomen and pelvis: evaluating "innocent bystander" tissues.

Radiographics. 2013

[8]
Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma.

J Korean Med Sci. 2013-1-29

[9]
The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011.

Liver Int. 2012-3-20

[10]
Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.

Int J Radiat Oncol Biol Phys. 2012-2-17

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索